{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:00:33Z","timestamp":1768993233503,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Co., Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Interv and Ther"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this real-world, retrospective cohort study of 9753 patients in Japan prescribed dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), we investigated DAPT duration and determined factors associated with early DAPT discontinuation and with event rates in patients who discontinued DAPT. The study period was April 1, 2012\u2013March 31, 2018; endpoints comprised composite efficacy [death, myocardial infarction (MI), and stroke] and bleeding (intracranial, gastrointestinal, and requiring transfusion) endpoints. Overall, 68.8% of patients were continuing DAPT at 3\u00a0months post-PCI. Patients without major efficacy or safety events within 3\u00a0months after index PCI were included in a landmark analysis set (LAS; <jats:italic>n<\/jats:italic>\u2009=\u20097056), and categorized as DAPT\u2009\u2265\u20093\u00a0months (continuation) versus\u2009&lt;\u20093\u00a0months (discontinuation). In the two LAS analysis groups, there was no difference in the composite bleeding endpoint (<jats:italic>P<\/jats:italic>\u2009=\u20090.067), although the incidence of the composite efficacy endpoint was higher in the discontinuation group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). In multivariate regression analysis, age\u2009\u2265\u200975\u00a0years, minor bleeding after PCI, history of cerebral infarction, history of cerebral or gastrointestinal bleeding, atrial fibrillation, dialysis, and anticoagulant use after PCI were associated with early DAPT discontinuation. Acute coronary syndrome, history of MI, kidney disorder, and anticoagulant use after PCI were associated with the composite efficacy endpoint in the discontinuation group. In conclusion, early DAPT discontinuation is more likely in patients at high bleeding risk, but may influence the occurrence of ischemic events in these patients. Determination of DAPT duration should take into account potential ischemic risk, even in patients at high bleeding risk.<\/jats:p>","DOI":"10.1007\/s12928-021-00833-z","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T17:02:43Z","timestamp":1644426163000},"page":"465-474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information database from Japanese hospitals"],"prefix":"10.1007","volume":"37","author":[{"given":"Hiroyoshi","family":"Yokoi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisei","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Matsubayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"833_CR1","unstructured":"Ministry of Health, Labour and Welfare. An overview of population statistics (approximate) in 2017; Table 7 [in Japanese]. https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jinkou\/geppo\/nengai17\/dl\/kekka.pdf. Accessed 30 March 2021."},{"key":"833_CR2","unstructured":"Japanese Registry of All Cardiac and Vascular Diseases (JROAD). Report on surveyed results for medical care of cardiac and vascular disease in 2013 [in Japanese]. http:\/\/jroadinfo.ncvc.go.jp\/cms\/wp-content\/uploads\/2015\/02\/report14_140115.pdf. Accessed 30 March 2021."},{"key":"833_CR3","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"SR Steinhubl","year":"2002","unstructured":"Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411\u201320.","journal-title":"JAMA"},{"key":"833_CR4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol. 2016;68:1082\u2013115.","journal-title":"J Am Coll Cardiol"},{"key":"833_CR5","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","volume":"84","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ J. 2020;84:831\u201365.","journal-title":"Circ J"},{"key":"833_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.7326\/M15-0083","volume":"163","author":"FA Spencer","year":"2015","unstructured":"Spencer FA, Prasad M, Vandvik PO, Chetan D, Zhou Q, Guyatt G. Longer- versus shorter-duration dual-antiplatelet therapy after drug-eluting stent placement: a systematic review and meta-analysis. Ann Intern Med. 2015;163:118\u201326.","journal-title":"Ann Intern Med"},{"key":"833_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11239-018-1707-1","volume":"46","author":"M Scherillo","year":"2018","unstructured":"Scherillo M, Cirillo P, Formigli D, Bonzani G, Calabr\u00f2 P, Capogrosso P, et al. Lights and shadows of long-term dual antiplatelet therapy in \u201creal life\u201d clinical scenarios. J Thromb Thrombolysis. 2018;46:559\u201369.","journal-title":"J Thromb Thrombolysis"},{"key":"833_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/heartjnl-2016-309509","volume":"103","author":"H Bueno","year":"2017","unstructured":"Bueno H, Pocock S, Danchin N, Annemans L, Gregson J, Medina J, et al. International patterns of dual antiplatelet therapy duration after acute coronary syndromes. Heart. 2017;103:132\u20138.","journal-title":"Heart"},{"key":"833_CR9","first-page":"1","volume":"11","author":"G Gao","year":"2020","unstructured":"Gao G, Zhao Y, Zhang D, Song C, Song W, Feng L, et al. Validation of the DAPT score in large-scale consecutive and contemporary patients population in the real world. Platelets. 2020;11:1\u20138.","journal-title":"Platelets"},{"key":"833_CR10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ijcard.2019.11.132","volume":"301","author":"M Bianco","year":"2020","unstructured":"Bianco M, D\u2019ascenzo F, Raposeiras Roubin S, Kinnaird T, Peyracchia M, Ariza-Sol\u00e9 A, et al. Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. Int J Cardiol. 2020;301:200\u20136.","journal-title":"Int J Cardiol"},{"key":"833_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.12.007","volume":"318","author":"M Zdanyte","year":"2021","unstructured":"Zdanyte M, Wrazidlo RW, Kaltenbach S, Groga-Bada P, Gawaz M, Geisler T, et al. Predicting 1-, 3- and 5-year outcomes in patients with coronary artery disease: a comparison of available risk assessment scores. Atherosclerosis. 2021;318:1\u20137.","journal-title":"Atherosclerosis"},{"key":"833_CR12","doi-asserted-by":"crossref","unstructured":"Kwok CS, Wong CW, Nagaraja V, Mamas MA. A systematic review of the studies that evaluate the performance of the DAPT score. Int J Clin Pract. 2020; 74:e13591.","DOI":"10.1111\/ijcp.13591"},{"key":"833_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1055\/s-0038-1676545","volume":"119","author":"J Kang","year":"2019","unstructured":"Kang J, Park KW, Palmerini T, Stone GW, Lee MS, Colombo A, et al. Racial differences in ischaemia\/bleeding risk trade-off during anti-platelet therapy: Individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost. 2019;119:149\u201362.","journal-title":"Thromb Haemost"},{"key":"833_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","volume":"11","author":"GN Levine","year":"2014","unstructured":"Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, et al. Expert consensus document: world heart federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11:597\u2013606.","journal-title":"Nat Rev Cardiol"},{"key":"833_CR15","unstructured":"National Institute of Public Health. Ethical guidelines on epidemiological research [in Japanese]. https:\/\/www.niph.go.jp\/wadai\/ekigakurinri\/rinrishishin.htm. Accessed 30 March 2021."},{"key":"833_CR16","first-page":"567","volume":"69","author":"K Murasaki","year":"2011","unstructured":"Murasaki K. Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease (JCS 2009) [in Japanese]. Nihon Rinsho. 2011;69:567\u201371.","journal-title":"Nihon Rinsho"},{"key":"833_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1253\/circj.CJ-66-0053","volume":"77","author":"JCS Joint Working Group","year":"2013","unstructured":"JCS Joint Working Group. Guidelines for secondary prevention of myocardial infarction (JCS 2011). Circ J. 2013;77:231\u201348.","journal-title":"Circ J"},{"key":"833_CR18","unstructured":"The Japanese Circulation Society. Guidelines for diagnosis and treatment of cardiovascular diseases (2012 joint working groups report). Guidelines for the management of patients with ST-elevation acute myocardial infarction (JCS 2013) [in Japanese]. http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2013_kimura_h.pdf. Accessed 11 August 2021."},{"key":"833_CR19","unstructured":"The Japanese Circulation Society. Guidelines for management of acute coronary syndrome without persistent ST segment elevation (JCS 2012) [in Japanese]. https:\/\/www.j-circ.or.jp\/old\/guideline\/pdf\/JCS2012_kimura_h.pdf. Accessed 11 August 2021."},{"key":"833_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2020.12.066","volume":"144","author":"S Patil","year":"2021","unstructured":"Patil S, Gonuguntla K, Rojulpote C, Kumar M, Nadadur S, Nardino RJ, et al. Prevalence and determinants of atrial fibrillation-associated in-hospital ischemic stroke in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol. 2021;144:1\u20137.","journal-title":"Am J Cardiol"},{"key":"833_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00392-020-01708-8","volume":"110","author":"A Sch\u00e4fer","year":"2021","unstructured":"Sch\u00e4fer A, Flierl U, Bauersachs J. Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI. Clin Res Cardiol. 2021;110:759\u201374.","journal-title":"Clin Res Cardiol"},{"key":"833_CR22","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1001\/jama.2019.8146","volume":"321","author":"JY Hahn","year":"2019","unstructured":"Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321:2428\u201337.","journal-title":"JAMA"},{"key":"833_CR23","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","volume":"321","author":"H Watanabe","year":"2019","unstructured":"Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321:2414\u201327.","journal-title":"JAMA"},{"key":"833_CR24","doi-asserted-by":"crossref","unstructured":"Nakamura M, Kadota K, Nakao K, Nakagawa Y, Shite J, Yokoi H, et al. Single antiplatelet therapy with prasugrel vs. dual antiplatelet therapy in Japanese percutaneous coronary intervention patients with high bleeding risk. Circ J. 2021; 85:785\u201393.","DOI":"10.1253\/circj.CJ-20-1058"},{"key":"833_CR25","unstructured":"National Statistics Center, Statistics Bureau, Ministry of Internal Affairs and Communications with the collaboration of Ministries and Agencies Patient Survey, Portal Site of Official Statistics of Japan [in Japanese]. http:\/\/www.e-stat.go.jp. Accessed 30 March 2021."},{"key":"833_CR26","doi-asserted-by":"crossref","unstructured":"Urushihara H, Taketsuna M, Liu Y, Oda E, Nakamura M, Nishiuma S, et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PLoS One. 2012; 7:e53224.","DOI":"10.1371\/journal.pone.0053224"},{"key":"833_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jjcc.2016.10.015","volume":"70","author":"Y Koretsune","year":"2017","unstructured":"Koretsune Y, Takeshi Y, Yasaka M, Ono Y, Hirakawa T, Ishida K, et al. Usefulness of a healthcare database for epidemiological research in atrial fibrillation. J Cardiol. 2017;70:169\u201379.","journal-title":"J Cardiol"}],"container-title":["Cardiovascular Intervention and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-021-00833-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12928-021-00833-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-021-00833-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T10:46:05Z","timestamp":1655203565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12928-021-00833-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["833"],"URL":"https:\/\/doi.org\/10.1007\/s12928-021-00833-z","relation":{},"ISSN":["1868-4300","1868-4297"],"issn-type":[{"value":"1868-4300","type":"print"},{"value":"1868-4297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"assertion":[{"value":"3 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HY has received lecture fees from Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., AstraZeneca, Merck Sharp & Dohme, Boston Scientific, and Terumo Co. and has received scholarship funding from Daiichi Sankyo Co., Ltd. EO and KK declare no conflict of interest. KM has received personal fees from Daiichi Sankyo Co. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study used de-identified data that were retrieved in an unlinked manner from the Medical Data Vision automated hospital information database; therefore, the study was exempt from obtaining informed consent from individual patients according to the local ethical guidelines for epidemiological research []. In accordance with current guidelines from the Japanese Ministry of Health, Labour and Welfare (Ethical Guidelines for Medical and Health Research Involving Human Subjects, 2015), since the study utilized information which was unlinked and anonymized, review by an ethical review committee was unnecessary; therefore, no approval was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}